Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus vitamin K antagonist or LMWH in pediatric heart disease requiring chronic anticoagulation
2016-001247-39Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apixaban in Cardiovascular Malformation (CVM) and Acquired cardiovascular disease (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Composite bleeding endpoint. Started Dec 2016; status: completed.
02
Drugs
apixaban
03
Conditions
Cardiovascular Malformation (CVM)Acquired cardiovascular disease
Beyond the preview
Go deeper on 2016-001247-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001247-39.